TEVA Latest Headlines

Teva outlines 2030 targets ahead of R&D Day event

at seekingalpha.com (Wed, 11-Nov 8:15 AM)

Teva halts a 350-patient Phase 2 MSA study after interim futility readout, with no safety issues flagged

Market Chameleon (Mon, 2-Nov 8:19 AM)

Teva Gains After FDA Clears WELTRUZA as the First Once-Monthly Subcutaneous Olanzapine for Adult Schizophrenia

Market Chameleon (Fri, 9-Oct 11:33 AM)

Teva Wins FDA Approval for WELTRUZA, a Once-Monthly Subcutaneous Olanzapine That Requires No Post-Injection Monitoring

Market Chameleon (Fri, 9-Oct 7:35 AM)

Teva Sets Nov. 3 Q3 2026 Results Call, Putting 8:00 a.m. ET on Investors’ Calendars

Market Chameleon (Thu, 24-Sep 8:42 AM)

FDA Grants Priority Review for Teva’s Ecopipam: A Decade-First Therapy Could Redefine Tourette Syndrome Care

Market Chameleon (Wed, 19-Aug 8:54 AM)